Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

BUY
$63.71 - $70.74 $6,434 - $7,144
101 Added 2.96%
3,518 $224,000
Q1 2023

May 02, 2023

SELL
$65.71 - $74.53 $15,047 - $17,067
-229 Reduced 6.28%
3,417 $236,000
Q4 2022

Feb 13, 2023

SELL
$68.48 - $81.09 $5,478 - $6,487
-80 Reduced 2.15%
3,646 $262,000
Q3 2022

Nov 14, 2022

BUY
$0.13 - $76.84 $0 - $76
1 Added 0.03%
3,726 $265,000
Q1 2022

May 10, 2022

BUY
$61.48 - $73.72 $61 - $73
1 Added 0.03%
3,725 $272,000
Q4 2021

Feb 07, 2022

SELL
$53.63 - $62.52 $26,761 - $31,197
-499 Reduced 11.82%
3,724 $232,000
Q2 2021

Jul 15, 2021

BUY
$61.91 - $67.42 $61 - $67
1 Added 0.02%
4,223 $282,000
Q1 2021

May 04, 2021

SELL
$59.34 - $66.74 $8,782 - $9,877
-148 Reduced 3.39%
4,222 $267,000
Q4 2020

Feb 09, 2021

SELL
$57.74 - $65.43 $4,099 - $4,645
-71 Reduced 1.6%
4,370 $271,000
Q3 2020

Nov 05, 2020

BUY
$57.43 - $63.64 $35,491 - $39,329
618 Added 16.17%
4,441 $268,000
Q2 2020

Aug 06, 2020

BUY
$54.82 - $64.09 $209,576 - $245,016
3,823 New
3,823 $225,000
Q1 2020

May 11, 2020

SELL
$46.4 - $67.43 $148,851 - $216,315
-3,208 Closed
0 $0
Q4 2019

Feb 10, 2020

BUY
$49.21 - $64.19 $157,865 - $205,921
3,208 New
3,208 $206,000
Q4 2018

Feb 05, 2019

SELL
$48.76 - $63.23 $167,734 - $217,511
-3,440 Closed
0 $0
Q3 2018

Oct 26, 2018

BUY
$55.19 - $62.25 $189,853 - $214,140
3,440 New
3,440 $214,000
Q2 2018

Aug 14, 2018

SELL
$50.53 - $62.98 $178,118 - $222,004
-3,525 Closed
0 $0
Q1 2018

May 14, 2018

SELL
$59.92 - $68.98 $145,306 - $167,276
-2,425 Reduced 40.76%
3,525 $223,000
Q4 2017

Feb 12, 2018

BUY
$59.94 - $65.35 $356,643 - $388,832
5,950
5,950 $365,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $113B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Aft, Forsyth & Company, Inc. Portfolio

Follow Aft, Forsyth & Company, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aft, Forsyth & Company, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Aft, Forsyth & Company, Inc. with notifications on news.